La FDA publie des rapports sur les PFAS et l'accès aux dossiers : Le projet de directive officiel doit être révisé !
Entering 2026, the regulatory hammer of the U.S. Food and Drug Administration (FDA) has fallen in rapid succession. Within just three weeks, the FDA released two critical documents targeting PFAS (“forever chemicals”) and records access authority. The release of these documents is no coincidence; they are direct products of the comprehensive implementation of the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). For companies exporting to the U.S., the threshold for compliance has been raised once again. I. PFAS Investigation Report: 51 Ingredients Named, Data Gaps Remain a Challenge On December 29, 2025, the FDA submitted its highly anticipated report on PFAS in cosmetics to Congress. This authoritative conclusion was derived from the first wave of product listing data under MoCRA. Core Findings: II. Records Access Guidance: What’s in the FDA’s “Inspection Kit”? On January 21, 2026, the FDA issued draft industry guidance regarding records access authority under Sections 605